TCWP Non interventional study: EASIX to predict alloSCT outcome.
PI: Olaf Penack and Thomas Luft.
Primary objective: To estimate the prognostic ability of EASIX before conditioning (i.e. at the day of hospital admission for alloSCT), at day of transplantation, at day 14 and at day 28 on 1-year NRM.
Inclusion Criteria:
- First alloSCT in children and adults with PBSCs (all donor types).
- Previous autoSCT is not an exclusion criterion.
- Patients with acute leukemia, MDS, MPN or lymphoma (all disease stages).
- Myeloablative and dose-reduced conditioning (all types of GVHD prophylaxis).
Expected study period: The inclusion period has been extended to May 31st 2020. Follow up will be till day +365 after alloSCT.
If you are interested in this study, please contact the Data office Paris at ebmt.do-paris@ebmt.org
TCWP Non interventional study: Complications of T cell-repleted haploidentical stem cell transplantation with post-transplant cyclophosphamide.
PI: Grzegorz Basak.
Primary objective: To document incidence and frequency of infectious and non-infectious complications after posttransplant cyclophosphamide-based haploSCT.
Inclusion Criteria:
- Adult patients (>=18y old at time of transplant).
- Patients in whom T cell-replete haploidentical stem cell transplantation with posttransplant cyclophosphamide has been performed between November 2017 and December 2019.
Expected study period: 2017-2022 (registration: 1st November 2017- end of inclusion extended to 30th June 2020, 2 years follow up).
If you are interested in this study, please contact the Data office Paris at ebmt.do-paris@ebmt.org
TCWP Retrospective study: Retrospective study on the incidence, severity, management and outcome of sinusoidal obstruction syndrome/ veno-occlusive disease of the liver in allogeneic haematopoietic stem cell transplantation in adult patients.
PI: Tapani Ruutu.
The landscape of sinusoidal obstruction syndrome / veno-occlusive disease of the liver (SOS/VOD) has changed considerably during the recent years. There have not been any satisfactory means to predict in an early phase which patients will develop severe SOS/VOD. Early prediction has become particularly important as effective treatment has become available, and early treatment has been shown to result in improved outcome.
Primary Objective: Objectives:
- To determine the present incidence of SOS/VOD in adult patients
- To evaluate the outcome of patients with SOS /VOD (survival, resolution of SOS/VOD), overall and in relation to the severity grade
- To describe the treatments given for SOS/VOD, regarding the severity grade
Conduct of the study:
All allogeneic EBMT centers treating adult patients will be invited by the Paris data office to participate in the study.
The study period will be a fixed period of one year, year 2018.
The centers which agree to participate will be provided with a list of their adult allogeneic transplant patients transplanted in 2018. They will be asked to report which of the patients had SOS/VOD and which did not.
Patients who developed SOS/VOD are reported in detail. In addition to the routine EBMT reporting, the centers report on a specific MedB/C form the SOS/VOD risk factors, SOS/VOD prophylaxis, data of diagnostic procedures, treatment and outcome.
After the initial MedB/C report, later follow-up will be according to the routine EBMT reporting.
No reporting of data from patients who do not develop SOS/VOD is requested for the present study.
Study population: Adult patients with SOS/VOD.
- Adults Patients transplanted in 2018·
- Allo transplantation
- SOS/VOD within 100 days post HSCT
- All diseases
Study period: patients transplanted in 2018. The deadline for the retrospective data collection is extended till the 28th February 2020
If you are interested in this study, please contact Mohamed Houhou at mohamed.houhou@umpc.fr
TCWP prospective study: SFAST : A cross-sectional study on the Sexual Function of Adult Survivors and their partners 3 and 15 years Post allogeneic Stem Cell Transplantation
PI: Corien Eeltink
Primary objective: to explore sexual functioning of alloHCT survivors (and their partners) at 2-4 years post HCT & at 14-16 years post HCT.
Inclusion Criteria:
- allogeneic SCT recipients (all diseases)
- Age ≥18 years
- 2 - 4 year or 14 - 16 years post transplantation at the time of data collection without major cognitive impairement
- Able to read and write in English, French, German, Italian or Dutch.
If you are interested in this study, please contact CQWPebmt@lumc.nl or c.eeltink@vumc.nl